Discovery of DS-1093a: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia
Naoki Tanaka(Kyushu University), Hisakuni Obayashi(Daiichi-Sankyo (Japan)), Takeshi Fukuda(Jikei University School of Medicine), Koji Sasaki(The University of Texas MD Anderson Cancer Center), Ken J. Ishii(The University of Tokyo), Shinichi Takahashi(Daiichi-Sankyo (Japan)), Takashi Tsuji(Fujita Health University), Masami Hashimoto(Daiichi-Sankyo (Japan)), Kyoji Yamaguchi(Daiichi-Sankyo (Japan)), Y. Niitsu(Daiichi-Sankyo (Japan)), Rieko Takano(Daiichi-Sankyo (Japan)), Takeshi Kuribayashi(Daiichi-Sankyo (Japan)), Riki Goto(Daiichi-Sankyo (Japan))
Cited by 3
Related Papers
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
|Proceedings of the National Academy of Sciences|1998|4.3k
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis
|Journal of Hepatology|1999|2.9k
Tumor Necrosis Factor α Stimulates Osteoclast Differentiation by a Mechanism Independent of the Odf/Rankl–Rank Interaction
|The Journal of Experimental Medicine|2000|1.3k
Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis<i>in Vitro</i><sup>1</sup>
|Endocrinology|1998|1.2k
RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis
|Biochemical and Biophysical Research Communications|1998|746